Nathan Fielder's Theranos documentary sparks debate over whether Elizabeth Holmes was a bad founder or a product of the TED Talk era

Nathan Fielder's Theranos Film Reignites a Core Question: Bad Founder or Product of an Era

Nathan Fielder's documentary "You Can See Everything" has triggered a debate about Elizabeth Holmes that cuts deeper than fraud. The film appears to be generating two conflicting reads. One segment of viewers comes away sympathetic to Holmes—seeing her as manipulated, perhaps misunderstood, a founder caught in circumstances beyond her control. Another reading, more grounded in operational reality, is that Holmes was simply a bad founder operating in an era when bad founders could get remarkably far.

The second reading holds more weight. Holmes had access to something more valuable than a working device: a cultural moment. Between 2011 and 2015, following the release of "The Social Network," an entire apparatus of venture capital, accelerators, and media infrastructure coalesced around young, charismatic founders with audacious claims. At conferences, hard-tech founders presented fraudulent products and fudged studies. Most adults in the room excused it as "faking it till you make it." Holmes didn't invent the playbook—she executed it better than anyone else and rode it longer.

The operational gap is stark. The medical device industry has a decades-old, proven playbook. Over 60 companies have sold for more than $100 million in the blood-testing category alone. The standard path: acquire IP, build the device, develop the supply chain, submit to FDA, wait years for approval, sell. Specific venture firms focus exclusively on this category. It is, by design, boring—and it works.

Holmes framed Theranos as revolutionary magic. What it actually was, had it worked, would have been routine. When asked to describe the product, she spoke vaguely of "a box" and "the cloud"—language that suggests either confusion about her own device or deliberate obscuration. She never acknowledged what was actually true: that building and selling a diagnostic box is a tractable, if unglamorous, business that happens repeatedly.

The contrast is instructive. Diego Ramirez, co-founder of a real diagnostics company that shipped a working device, approached the problem with narrow focus. The device tested for antibiotic-resistant bacteria in hospitals. It shrunk a lab instrument from dishwasher-size to deployable in-hospital equipment. The chemistry wasn't magic—particles that light up when exposed to resistant bacteria, then a light detector measures the signal. If you can get results in an hour instead of two days, hospitals run smoother, patients get better outcomes. The company raised $25 million, sold for $425 million, and Roche took it through FDA approval. The product shipped under the FDA-approved name COBOS VivoDx MRSA test. The particles that detect the bacteria are called "smarticles"—a name that sounds absurd but represents real science.

Holmes never would have framed a company this way. She required the narrative to be world-changing, impossible, uniquely her vision. That was the TED Talk era speaking through her.

When that era ended—when the world "suddenly woke up," as one observer notes—Holmes kept running the same playbook in the most regulated industry available: medical devices. The FDA doesn't permit founders to go on podcasts claiming unproven efficacy. You can't say your device works; you can only say you're working on it. You can't market what you haven't been authorized to market. Holmes violated this not out of necessity but out of habit. She treated a highly regulated, well-charted industry as if it operated under the rules of venture mythology.

The documentary does not show her as having deep scientific knowledge. Billy Balwani learns about mitochondria on screen. Holmes locks in on no science-related thesis. If she had survived prison as a wrongfully convicted genius, you would expect her to have continued reading literature, developing theses about biotech evolution, making predictions that could be verified over time. Instead, there is no evidence of that capability in the film.

The redemption narrative now circulating on social media—driven partly by Holmes posting funny, edgy content on X and drawing viral attention—conflates comedy with competence and social media rehabilitation with business acumen. Being funny does not make you a good founder. It does not make you innocent. And it certainly does not make you understand your industry.

If Holmes wanted to demonstrate that she had learned something, she could post a detailed market map of the biotech acquisition space, a tier list of medical device companies, or a 2027 thesis about peptides or another emerging category. She could show she understands what Roche actually does and where real innovation is happening. Instead, what emerges from the documentary is that she understood narrative better than she understood biology, chemistry, medicine, or business operations. She was a world-class pitch person deployed in a field where pitches matter far less than results.

Both Holmes and co-founder Sunny Balwani received prison sentences—Holmes 11 years, Balwani 12 years—and critically, neither appears to have cooperated with the other to reduce their sentence. Neither secured reduced time by testifying against the other. Neither sold secondary shares to cash out before conviction. The film suggests Sunny may have attempted to engineer a financial arrangement through Billy Balwani to shield earnings from restitution claims, but the underlying fact remains: two people perpetrated systematic fraud in a heavily regulated industry and faced equivalent, lengthy consequences.

The documentary is a commercial success—$15 million opening weekend, likely to have sustained cultural resonance given Fielder's body of work. Whether it serves as a cautionary tale or a sympathy vehicle depends on the viewer's starting assumption about who Holmes was: a visionary undone by circumstance, or a poor operator who thrived briefly in an era that celebrated style over substance, then crashed when the era ended and her product never materialized.